Navigation Links
JHP Pharmaceuticals to Produce Supplies of Biologic Drug Product for Late-Phase Clinical Trials
Date:4/17/2013

PARSIPPANY, N.J., April 17, 2013 /PRNewswire/ -- JHP Pharmaceuticals, a leading provider of global contract manufacturing services for sterile products has entered into an agreement with an undisclosed biotechnology company to produce clinical supplies of a biologic for late-phase clinical trials.

JHP's cGMP compliance history was a critical factor in the selection process. Stuart Hinchen , CEO stated, "Our record of cGMP compliance, driven by experienced Quality and Regulatory Teams continues to be one of the key reasons customers choose JHP. Additionally, both new and established customers recognize our approach to ongoing investment in people and facilities. As an example, last year we broke ground on a new $10 million, 40,000 sq. ft. laboratory that will house QC Chemistry and Method Transfer, Sterility Assurance and Stability. This type of investment allows us to focus on customer needs, which results in sustainable sales growth."

Hinchen noted, "Our use of disposable product contact equipment is another leading factor in the selection process. JHP's strategic use of disposables provides our customers with manufacturing process efficiencies that result in reduced cycle time."

JHP Pharmaceuticals' Rochester, Michigan facility has over 25 years' experience in contract manufacturing. Expertise in seamlessly progressing from clinical batch production to commercialization provides customers with continuity of supply and program efficiencies. A comprehensive suite of services including Regulatory, Analytical Methods Development, Package Engineering, Stability Testing and Validation also support contract manufacturing customers. JHP has successfully supported launches of several products in US and international markets and manufactures products for sale in 86 countries.

About JHP Pharmaceuticals, LLC
JHP Pharmaceuticals, headquartered in '/>"/>

SOURCE JHP Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Royalty Rates for Pharmaceuticals & Biotechnology: Real-Deal Information for Hundreds of Transactions
2. Omthera Pharmaceuticals, Inc. Announces Closing of Initial Public Offering
3. Avion Pharmaceuticals, LLC., announces further expansion of their Womens Health Sales Team
4. Oramed Pharmaceuticals Appoints New Chief Operating Officer and VP of Business Development
5. Valeant Pharmaceuticals To Announce 2013 First Quarter Results On May 2, 2013
6. RoundTable Healthcare Partners and Argon Medical Devices Complete Acquisition of Angiotech Pharmaceuticals Interventional Products Business
7. Kinex Pharmaceuticals Chief Scientific Officer, Dr. David Hangauer, named the American Cancer Societys 2013 Honoree for its Cuisine for a Cure event
8. Omthera Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering
9. Merrimack Pharmaceuticals Preclinical Research Shows MM-111 Restores Sensitivity To Chemotherapy And HER2-targeted Treatment In Gastric Cancer Model
10. Inovio Pharmaceuticals & U.S. Army Receive $3.5 Million Biodefense Grant to Further Develop Mass Vaccination Device
11. Faruqi & Faruqi, LLP is Investigating Peregrine Pharmaceuticals Inc. on Behalf of its Shareholders - PPHM
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... 2015  SurgiQuest®, Inc. ("SurgiQuest", the "Company"), a ... invasive surgery (MIS) announced today that surgeons have ... procedures.  Adoption has risen rapidly with a 150% ... by the company,s expansion from robotics into the ... to over 45 countries.   The ...
(Date:6/3/2015)... , June 02, 2015 Research and ... of the "Global Neurodegenerative Diseases Market 2015-2019" ... global neurodegenerative diseases market to grow at a ... This report covers the present scenario and ... market for the period 2015-2019. To calculate the ...
(Date:6/3/2015)... 2015  EIP Pharma LLC ( www.eippharma.com ) today ... of VX-745 in Alzheimer,s disease (AD) is underway.  VX-745 ... inhibitor of the alpha isoform of the protein enzyme ... "Recent human genetic data demonstrate that inflammation is ... Alzheimer,s, while the science also indicates the p38 MAPK ...
Breaking Medicine Technology:Rapid Procedure Growth With SurgiQuest's AirSeal System 2Global Neurodegenerative Diseases Market 2015-2019 - Reformulation of Marketed Drugs 2EIP Pharma announces first patient dosing in phase 2 clinical studies of a novel brain-targeted anti-inflammatory drug candidate, VX-745, for the treatment of Alzheimer's disease (AD) 2EIP Pharma announces first patient dosing in phase 2 clinical studies of a novel brain-targeted anti-inflammatory drug candidate, VX-745, for the treatment of Alzheimer's disease (AD) 3
... Inc. ( www.bendresearch.com ), a leading independent drug-formulation development and ... Jim Nightingale, who has worked at the company since 1993, ... Nightingale will succeed Rod Ray, who will ... (CEO) and chairman of the board of directors. ...
... Mass., July 27, 2011 Magellan Biosciences, a ... testing easier, more cost-effective, and less labor intensive, ... Atlanta yesterday at the AACC Clinical Lab Expo. ... laboratories seeking to improve the workflow efficiency, cost-effectiveness, ...
Cached Medicine Technology:Bend Research Inc. Names New President 2Magellan's Dynex® Agility™ ELISA Processor Dramatically Reduces Laboratory Time and Labor in Diagnostic Testing While Ensuring the Most-Accurate Results 2Magellan's Dynex® Agility™ ELISA Processor Dramatically Reduces Laboratory Time and Labor in Diagnostic Testing While Ensuring the Most-Accurate Results 3
(Date:6/3/2015)... PINES, FL (PRWEB) June 03, 2015 The ... event as part of the Veterans Health Administration’s (VHA) National ... place in the JC Cobb room located on the first ... 10:00 a.m. to 4:00 p.m. Women Veterans and their ... are invited to attend. To download a printable event flyer, ...
(Date:6/3/2015)... Norcross, GA (PRWEB) June 03, 2015 ... officially named the winner of its 2015 U.S. Education ... Power Portfolio in a college or university in the ... a GIScience student focused on Remote Sensing and Civil ... winning study, titled, “Pavement Surface Cracks Detection and Assessment ...
(Date:6/3/2015)... (PRWEB) June 03, 2015 Johnson & ... pay $7.8 million to resolve a Risperdal lawsuit ( ... tactics the company allegedly used to market the antipsychotic ... Court indicate that the Arkansas Attorney General moved to ... the accord. The Risperdal settlement amounts to just a ...
(Date:6/3/2015)... 2015 On June 22, 2015, Medicare ... drug sensitivity (pharmacogenetic) testing that it has reimbursed since 2009. ... as 19 million of the 49 million Medicare beneficiaries in ... life-threatening adverse drug events.(1) Sadly, if it became a standard ... Medicine, the use of an individual’s genetic information to tailor ...
(Date:6/3/2015)... Array Health , a leading ... that CEO Jonathan Rickert will present at America’s ... 4, 2015. The session will address the how the ... business models in health care, and why they are ... Digital Transformation and the Health Care Enterprise: Driving Business ...
Breaking Medicine News(10 mins):Health News:Bay Pines to Host National Women Veterans Campaign Event June 12 2Health News:Bay Pines to Host National Women Veterans Campaign Event June 12 3Health News:Hexagon Geospatial Announces U.S. Education Challenge Winner at HxGN Live 2015 2Health News:Risperdal Lawsuit News: Johnson & Johnson, Janssen Settle Arkansas Marketing Case for $7.8 Million 2Health News:Risperdal Lawsuit News: Johnson & Johnson, Janssen Settle Arkansas Marketing Case for $7.8 Million 3Health News:Risperdal Lawsuit News: Johnson & Johnson, Janssen Settle Arkansas Marketing Case for $7.8 Million 4Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 2Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 3Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 4Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 5Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 6Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 7Health News:Array Health’s CEO to Present at America’s Health Insurance Plans Institute 2015 2
... the pain-balm segment, with a market share of 70 ... Amrutanjan, Tiger Balm (locally manufactured by Elder Pharma), Zandu ... SmithKline India (GSK) has decided to transfer its Iodex ... a GSK subsidiary. SKBCH has a strong marketing and ...
... the most common cancer among women. It accounts for ... more than 23,000 new cases diagnosed in 2001. Progestin ... the highest// level of protection against ovarian cancer. Analysis ... study showed that the pill can help prevent ovarian ...
... disease that affects at least 39 million Americans, and ... to describe the problem. One in five Americans is ... raises the risk of many potentially fatal health conditions//, ... is linked to at least 300,000 deaths in the ...
... studying eight cross-gender heart transplants from New York Medical ... the heart after injury.// The research explodes the long-standing ... finding has implications for heart disease treatment. ... damaged heart much as it does other organs came ...
... non-steroidal anti-inflammatory drug (NSAID) treatment has shown that ... the risk of ulcer formation.// Treatment with omeprazole ... infections and reduced the six-month ulcer probability of ... to 12 per cent in the NSAID-treated arthritis ...
... discovered molecules in the body that can protect ... research, the research could potentially lead to the ... been linked with ailments such as cardiovascular disease, ... and Alzheimer’s disease. ,The researchers from ...
Cached Medicine News:
With the Symphony family of Pacemakers, Ela presents the most advanced technology on the market. Symphony, lighter than a passport, will take your patients further, offering fast follow-up, using new...
Gentle curve facilitates less traumatic removal from eye. Increased length ideal for myopic eyes...
Sleeve extends 3mm beyond end, .90mm (20G) probe, 1.4mm (17G) sleeve...
Ideal for short scleral tunnel and trabecular meshwork incisions...
Medicine Products: